StreetAlpha.app
Home › Stocks › ABOS

Acumen Pharmaceuticals, Inc. (ABOS)

$0.19
▼ −3.52%
LAST CLOSE · NOV 20

Acumen Pharmaceuticals develops experimental antibody treatments for Alzheimer's disease. It last closed at $0.19 on Nov 20, down 3.52% on the day. The next earnings report for ABOS is expected around Thu, Mar 25, 2027. For the quarter ended Sep 2026, ABOS reported EPS of -$0.35. Over its last 8 reports the stock moved an average of 5.1% the session after earnings. Over the last 12 months ABOS insiders bought $0 of stock on the open market and sold $626K, according to SEC Form 4 filings.

AI Auto Pilots
Is ABOS in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold ABOS.

Key Stats

Last 12 months
Results
Net income
−$104.0M
EPS (diluted)
−$1.55
Free cash flow
−$88.0M
Valuation
Market cap
$13.5M
72.3M shares
P/E
–
No P/E while losing money
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$53.1M
At Sep 30
Debt
$5.9M
At Sep 30
Shareholder equity
$34.6M
Shares outstanding
72.3M
At Oct 21
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: −$100.6M−$100.6MFY2021FY2022: −$42.9M−$42.9MFY2022FY2023: −$52.4M−$52.4MFY2023FY2024: −$102.3M−$102.3MFY2024FY2025: −$121.3M−$121.3MFY2025

From ABOS's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Oct 26). Last 12 months adds up the four latest quarters.

Next report
Mar 25
Estimated date · Time not announced
Reported EPS
-$0.35
Quarter ended Sep 2026
Year ago EPS
-$0.44
Same quarter last year
Revenue
—
Last reported quarter
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: -$0.62Dec '24Mar 2025: -$0.48Mar '25Jun 2025: -$0.68Jun '25Sep 2025: -$0.44Sep '25Dec 2025: -$0.41Dec '25Mar 2026: -$0.33Mar '26Jun 2026: -$0.45Jun '26Sep 2026: -$0.35Sep '26Latest -$0.35
Revenue by quarter
Not enough quarters on file yet.
How ABOS moved after its last 8 reports
Average move the session after a report ±5.1%
Oct 26, 2026Time not announced+14.7%
Aug 12, 2026Time not announced+1.6%
May 12, 2026Time not announced−3.5%
Mar 26, 2026Time not announced−3.0%
Nov 12, 2025Time not announced−1.0%
Aug 12, 2025Time not announced−11.3%
May 13, 2025Time not announced0.0%
Mar 27, 2025Time not announced+6.0%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on ABOSStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on ABOS
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on ABOS

Technical Analysis

ABOS · as of the Nov 20 close · updated each morning
Downtrend, oversold

The stock is 240% below its 20 day and 741% below its 50 day average. It is 1158% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 22), oversold. The nearest support is the Pivot at $0.18, and the nearest resistance the Pivot R1 at $0.20.

Short trendBearish
Long trendBearish
MomentumWeak
StretchOversold
VolatilityHigh, 67.9%/day
Key levels
$3.6052 week high+1794.7%
$2.35200 day average+1136.8%
$2.09100 day average+1000.0%
$1.5750 day average+726.3%
$0.6320 day average+231.6%
$0.23Swing high (Nov 17)+21.1%
$0.20Pivot R1+5.3%
$0.19Last close
$0.18Pivot−5.3%
$0.17Pivot S1−10.5%
$0.1652 week low−15.8%
Indicators
RSI (14)21.56Oversold below 30Oversold
MACD-0.44Above its signal lineBullish
Stochastic17.5Near the bottom of its rangeOversold
ADX (14)44.1Strong downtrend
Williams %R-70.4Oversold below −80, overbought above −20Neutral
CCI (20)-45.7Oversold below −100, overbought above 100Neutral
Rate of change−16.6%Change over 10 sessionsBearish
ATR (14)$0.13Typical daily range, 67.9% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for ABOS

What happened before

See how ABOS did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow ABOS usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How ABOS has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2021.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for ABOSHow many large options trades hit ABOS, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

ABOS Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Neutral
Strongly bearishNeutralStrongly bullish
  • ▲38 buying vs 33 selling
  • ▲Held by funds +1.1 pts
  • ▼Funds holding -1
  • ▼Superinvestors: 0 added, 3 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding9596−1.0%
In funds' top 1000–
Held by funds67.2%66.2%+1.1 pts
New / increased8 / 3030 / 20−24.0%
Reduced / sold out23 / 1015 / 17+3.1%
Put/call ratio0.00––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See ABOS institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

ABOS Insider Trading

All filings →
Insider trading · 12 months
Insiders are only selling
Bought$00 buys · 0 insiders
Sold$626K21 sales · 9 insiders
14% of the selling was under pre-arranged trading plans.
2026-01 sold $501K2026-02 sold $28K2026-03 sold $7K2026-06 sold $90KDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Jun 17Derrell PorterDirectorSale32,300$2.33$75K
Jun 9Nathan B FountainDirectorSale6,400$2.23$14K
Mar 6Derek M MeisnerChief Legal Officer & Corp SecSale plan2,090$3.26$7K
Feb 27Derek M MeisnerChief Legal Officer & Corp SecSale plan9,406$3.01$28K
Jan 28Derek M MeisnerChief Legal Officer & Corp SecSale plan17,756$3.00$53K
Jan 23Derek M MeisnerChief Legal Officer & Corp SecSale8,934$1.87$17K
Every insider buy and sale for ABOS over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See ABOS insider trades →

From SEC Form 4 filings by ABOS's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether ABOS is in one of them and how their past ABOS trades turned out.

ABOS in the AI portfolios
Loading…

ABOS News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered ABOS in an article yet. Here's the latest on the wider market.

ABOS in the news

About Acumen Pharmaceuticals

Acumen Pharmaceuticals is a biopharmaceutical company based in Newton, Massachusetts, that is developing treatments for Alzheimer's disease. Its lead candidate, sabirnetug, is an antibody designed to target soluble amyloid-beta oligomers, which the company believes play a central role in the disease. Sabirnetug is in a Phase 2 trial for people with mild cognitive impairment or mild dementia due to Alzheimer's. The company is also developing a brain-delivery platform with a partner and does not yet have a product on the market.

Headquarters
Newton, MA